Seeking Alpha

Acadia (ACAD) +6.4% after saying that its Pimavanserin performed well in a Phase III trial,...

Acadia (ACAD) +6.4% after saying that its Pimavanserin performed well in a Phase III trial, showing a "robust and consistent efficacy...across a wide array of study measures" and confirming previous "positive top-line results." Twice as many patients treated with pimavanserin were rated as "very much improved or much improved" vs those given a placebo. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|